Adenomyoepithelial adenosis of the breast is a form of adenosis not previously described. It is similar in several ways to microglandular adenosis, but one significant difference is the presence of myoepithelial cells. The present case originated as adenomyoepithelial adenosis in a 46-year-old woman. In the course of 18 years it proliferated and changed into a low-grade malignant adenomyoepithelioma. Electron microscopy confirmed the presence of myoepithelial cells in the adenosis, and immuno-histochemical study demonstrated cells containing actin (representing myoepithelial cells) in the adenosis as well as in the adenomyoepithelioma.

No abstract

No abstract

In an attempt to create uniform nationwide guidelines for the management of all stages of endometrial carcinoma, and to limit the use of adjuvant radiation therapy in stage I disease to high‐risk patients only, a protocol was developed by the Danish Endometrial Cancer group (DEMCA). From September 1986 through August 1988, 1214 women in Denmark with newly diagnosed carcinoma of the endometrium have been treated according to this protocol. This figure represents all endometrial carcinomas diagnosed in Denmark during this 2‐year period. The primary treatment was total abdominal hysterectomy and bilateral salpingo‐oophorectomy and no preoperative radiation therapy was delivered. In 1039 cases no macroscopic residual tumor and/or microscopic tumor tissue in the resection margins was found following surgery. Based on surgery and histopathology, these patients were classified as: P‐stage I low‐risk (grade 1 & 2 and 50% myometrial invasion), P‐stage I high‐risk (grade 1 & 2 and> 50% myometrial invasion, and grade 3), P‐stage II and P‐stage III (Group 1). Distribution was as follows: P‐I low‐risk 641 patients, P‐I high‐risk 235, P‐II 105 and P‐III (Group 1) 58 patients. No postoperative radiation therapy was given to P‐I low‐risk cases. P‐I high‐risk, P‐II, and P‐III (Group 1) cases received external radiation therapy. Recurrence rate at 68–92 months follow‐up was 45/641 (7%) in P‐I low‐risk, 36/235 (15%) in P‐I high‐risk, 30/105 (29%) in P‐II, and 27/58 (47%) in P‐III (Group 1) cases. Fifteen of 17 vaginal recurrences in P‐I low‐risk cases were salvaged (mean observation time 61 months).

No abstract